Adicet Bio, Inc. — Director's Dealing 2020

Sep 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adicet Bio, Inc. (ACET)
CIK: 0001720580
Period of Report: 2020-09-15

Reporting Person: Galimi Francesco (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-09-15	Employee Stock Option (right to buy)	$5.97	A	128424	Acquired	2029-10-15	Common Stock (128424)	Direct
2020-09-17	Incentive Stock Option (right to buy)	$16.11	A	77269	Acquired	2030-09-16	Common Stock (77269)	Direct

Footnotes

F1: 25% of the option will vest on September 23, 2020, and 1/36th of the remaining unvested option will vest on each of the next thirty-six (36) monthly anniversaries thereafter, provided that Dr. Galimi remains in continuous service as of the applicable vesting date.

F2: Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.740 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc."

F3: 1/48th of the shares of common stock subject to the option shall vest on each of the forty-eight (48) monthly anniversaries of the vesting commencement date, provided that Dr. Galimi remains in continuous service as of the applicable vesting date.